Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895361 | 0.86 | NOTUM (1.00) | NOTUMDRD2DRD4UCHL1 | |
| SCHEMBL30730960 | 0.86 | NOTUM (1.00) | NOTUMDRD2DRD4UCHL1 | |
| SCHEMBL6690150 | 0.85 | NOTUM (0.72) | NOTUMCYP2D6CYP2C9DRD2DRD4 | |
| SCHEMBL3300094 | 0.80 | NOTUM (0.68) | NOTUMDRD2DRD4POLBUCHL1 | |
| SCHEMBL13390819 | 0.80 | NOTUM (0.68) | NOTUMCYP2D6CYP2C9DRD2DRD4 | |
| SCHEMBL13390815 | 0.80 | NOTUM (0.68) | NOTUMDRD2DRD4POLBUCHL1 | |
| SCHEMBL6687673 | 0.78 | NOTUM (0.71) | NOTUMCYP2D6CYP2C9POLB | |
| SCHEMBL3300297 | 0.78 | NOTUM (0.71) | NOTUMCYP2D6CYP2C9POLB | |
| SCHEMBL4532424 | 0.78 | NOTUM (0.71) | NOTUMCYP2D6CYP2C9POLBUCHL1 | |
| SCHEMBL2619231 | 0.78 | NOTUM (1.00) | NOTUMCYP2D6CYP2C9DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642785-B2 | Photolabile dinitroindolinyl based compounds | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-20100096252-A1 | PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2008094922-A1 | PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2004085394-A1 | 7-NITROINDOLINE DERIVATIVES AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100096252-A1 | PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS | AANAT, TPH2, HTR3C | NOTUM 2995/4885CYP2D6 3218/4885CYP2C9 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.